Join to View Full Profile
6560 Fannin StSte 802Houston, TX 77030
Phone+1 713-441-1150
Fax+1 713-793-7012
Dr. Faridar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Methodist Hospital (Houston)Fellowship, Dementia Translational Fellowship, 2017 - 2018- Methodist Hospital (Houston)Residency, Neurology, 2013 - 2017
University of California San Francisco School of MedicinePost-Doctoral Fellowship, 2011 - 2013
Tehran University of Medical Sciences School of MedicineClass of 2008
Certifications & Licensure
TX State Medical License 2017 - 2026
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- BrightFocus Alzheimer Disease Research Fellowship Award 2019
- American Neurology Association (ANA) travel award 2013
Clinical Trials
- Phase II Clinical Trial of Interleukin-2 in AD Start of enrollment: 2022 Jan 01
Roles: Contact, Principal Investigator
- Systemic and Central Inflammation in AD Start of enrollment: 2023 Mar 17
Roles: Contact
- IL-2 Plus Abatacept in FTD Start of enrollment: 2024 May 06
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 5 citationsBrain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer's disease.Johanna Appleton, Quentin Finn, Paolo Zanotti-Fregonara, Meixiang Yu, Alireza Faridar
Brain. 2025-01-07 - 3 citationsA phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic...Jason R Thonhoff, David R Beers, Weihua Zhao, Alireza Faridar, Aaron Thome
Frontiers in Neurology. 2024-01-01 - 10 citationsA phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.Alireza Faridar, Abdulmunaim M Eid, Aaron D Thome, Weihua Zhao, David R Beers
Translational Neurodegeneration. 2023-11-16
Press Mentions
Coya Therapeutics Reports Data from Alzheimer’s Disease Therapy TrialApril 3rd, 2023- Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s DiseaseJune 10th, 2023
- Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceMarch 1st, 2024
- Join now to see all
Grant Support
- Multi-omic integrative analysis of shared and distinct inflammation networks across neurodegenerative disordersMETHODIST HOSPITAL RESEARCH INSTITUTE2024–2025
- Multi-omic integrative analysis of shared and distinct inflammation networks across neurodegenerative disordersMETHODIST HOSPITAL RESEARCH INSTITUTE2024–2025
- Multi-omic integrative analysis of shared and distinct inflammation networks across neurodegenerative disordersMETHODIST HOSPITAL RESEARCH INSTITUTE2024–2025
- Central and peripheral immune cross-talk in Alzheimer's disease and their modulation by a novel immunotherapyMETHODIST HOSPITAL RESEARCH INSTITUTE2023–2025
- Central and peripheral immune cross-talk in Alzheimer's disease and their modulation by a novel immunotherapyMETHODIST HOSPITAL RESEARCH INSTITUTE2023–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
